Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Drug Accumulation During Multiple Dosing: Repetitive IV Injections01:21

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
Nonlinear Pharmacokinetics: Drug Elimination for IV Bolus Injection00:59

Nonlinear Pharmacokinetics: Drug Elimination for IV Bolus Injection

In pharmacokinetics, the elimination rate of a drug following a capacity-limited model is primarily controlled by two parameters: Vmax and KM. These parameters are crucial in how the drug behaves inside the body after administration.
Following the administration of a single intravenous (IV) bolus injection, we can determine the concentration of the drug in the plasma at any given time. This calculation is achieved using a specific equation that integrates the values of Vmax and KM.
We can also...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Living-donor Kidney Transplantation After Resection of Mixed Epithelial and Stromal Tumor: A Positive Outcome Despite Not Observing the Recommended Waiting Period.

Cancer diagnosis & prognosis·2026
Same author

Robot-assisted Complete Urinary Tract Exenteration for Multifocal Urothelial Carcinoma: Perioperative Management in Non-dialysis Patients.

Anticancer research·2026
Same author

Improving Gallbladder Cancer Outcomes with Antibody-Based Therapies and Immunological Profiling: A Literature Review.

Antibodies (Basel, Switzerland)·2026
Same author

Spatial Analysis Identifies Endothelial HLA-F as a Prognostic Marker in Antibody-mediated Rejection.

Transplantation·2026
Same author

Belzutifan for Metastatic TFE3-Rearranged Renal Cell Carcinoma With Pulmonary Metastases: A Case Report.

IJU case reports·2026
Same author

Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker.

Targeted oncology·2026

Related Experiment Video

Updated: Jun 5, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized,

Ignacio A Casarini1, Dariusz M Kowalski2, Christian Caglevic3

  • 1Hospital Bernardo A. Houssay, Mar del Plata, and Facultad de Medicina, Universidad Nacional de Mar del Plata, Mar del Plata, Buenos Aires, Argentina.

JCO Oncology Practice
|June 3, 2026
PubMed
Summary
This summary is machine-generated.

Patients preferred subcutaneous pembrolizumab over intravenous pembrolizumab due to convenience. Subcutaneous pembrolizumab (pembrolizumab with hyaluronidase alfa) offers a more convenient option for cancer treatment.

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Related Experiment Videos

Last Updated: Jun 5, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Pembrolizumab is an immunotherapy drug used to treat various cancers.
  • Subcutaneous (SC) pembrolizumab, formulated with hyaluronidase alfa, offers an alternative administration route to intravenous (IV) pembrolizumab.
  • Patient preference and convenience are crucial factors in treatment adherence and satisfaction.

Purpose of the Study:

  • To assess participant preference between SC and IV pembrolizumab.
  • To evaluate reasons for preference, satisfaction, and continued treatment choice.
  • To compare the safety and tolerability of SC versus IV pembrolizumab administration.

Main Methods:

  • Phase II, open-label, crossover study (NCT06099782) involving 147 participants with resected melanoma, renal cell carcinoma, or metastatic non-small cell lung cancer.
  • Participants received three cycles of SC or IV pembrolizumab, then crossed over to the other route for three cycles.
  • Primary endpoint was participant preference for SC pembrolizumab, assessed via the Patient Preference Questionnaire.

Main Results:

  • 65% of participants preferred SC pembrolizumab over IV.
  • The primary reason for SC preference was reduced clinic time (64%).
  • Higher satisfaction rates were reported for SC (89%) versus IV (85%) pembrolizumab; 68% chose SC for continued treatment.

Conclusions:

  • Subcutaneous pembrolizumab was preferred by the majority of participants over IV administration.
  • Pembrolizumab SC demonstrates improved convenience and patient satisfaction compared to IV pembrolizumab.
  • SC pembrolizumab represents a viable and convenient alternative for cancer immunotherapy.